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Abstract
Background Treatment of neuropathic pain is still challenging. Recent studies have suggested that dorsal root ganglia (DRG), 
which carry sensory neural signals from the peripheral nervous system to the central nervous system, are important for 
pathological nociception. A proper understanding of the significance and function of DRG and their role in pharmacotherapy 
can help to improve the treatment of neuropathic pain. Metamizole, also known as sulpyrine or dipyrone, is a non-opioid 
analgesic commonly used in clinical practice, but it is not used for neuropathic pain treatment.
Methods Chronic constriction injury (CCI) of the sciatic nerve was induced in Wistar rats. Metamizole was administered 
intraperitoneally (ip) preemptively at 16 and 1 h before CCI and then twice a day for 7 days. To evaluate tactile and thermal 
hypersensitivity, von Frey and cold plate tests were conducted, respectively.
Results Our behavioral results provide evidence that repeated intraperitoneal administration of metamizole diminishes the 
development of neuropathic pain symptoms in rats. Simultaneously, our findings provide evidence that metamizole diminishes 
the expression of pronociceptive interleukins (IL-1beta, IL-6, and IL-18) and chemokines (CCL2, CCL4, and CCL7) in DRG 
measured 7 days after sciatic nerve injury. These assays indicate, for the first time, that metamizole exerts antinociceptive 
effects on nerve injury-induced neuropathic pain at the DRG level.
Conclusions Finally, we indicate that metamizole-induced analgesia in neuropathy is associated with silencing of a broad 
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Introduction
Chronic pain occurs in approximately 20% of the general 
population [1], and the prevalence of neuropathic pain is 
6.9% [2]. In a review [3] based on 174 published clinical tri-
als, it was reported that there are no drug treatments availa-
ble that can relieve all neuropathic pain conditions. Recently, 
accumulating evidence has demonstrated that neuroinflam-
mation at the level of dorsal root ganglia (DRG) is strongly 
involved in peripheral nerve injury-induced pain [4–11]. 
DRG contain the greatest proportion of sensory neurons, 
the cells that are primarily responsible for transduction of 
sensory information from the periphery and for transmit-
ting this information to the central nervous system. DRG are 
active participants in peripheral processes, including inflam-
mation and neuropathic pain development. Current meth-
ods for reducing neuropathic pain directly in DRG include 
ablation via continuous thermal radiofrequency, pulsed 
radiofrequency, or electrical neurostimulator technologies 
and modification of DRG cellular function using viral vec-
tors and gene silencing [12]. Pharmacological blockade of 
DRG via intraforaminal epidural administration of lidocaine 
results in relief of painful sensations in patients with phan-
tom limb pain [13]. Therefore, DRG neurons seem to be an 
ideal target for treatment of chronic pain, and it is important 
to study the role of neuroimmune interactions in DRG after 
the administration of analgesics. Nerve injury activates noci-
ceptive pathways and changes gene expression in DRG neu-
rons, which may contribute to the development and mainte-
nance of neuropathic pain. Current studies have described 
immune-related factors in DRG that are key players in the 
sensitization occurring under neuropathic pain [7–11, 14].
Metamizole (dipyrone, sulpyrine) is a non-opioid analge-
sic with antispasmodic and antipyretic properties. Metami-
zole was introduced in the clinic for the first time in 1922 in 
Germany and has since been used worldwide for treatment 
of several painful conditions, including postsurgical pain, 
colic pain and migraine [15–17]. Although metamizole has 
been used in the clinic for many years, its mechanisms of 
action are not entirely clear or fully understood. This drug 
is used to relieve somatic and visceral pain but not to treat 
neuropathic pain, although some of its mechanisms of action 
indicate potential therapeutic properties. The reason for 
this state of affairs is primarily the small number of basic 
experimental studies and the even smaller number of clini-
cal trials assessing the efficacy of metamizole in the treat-
ment of neuropathic pain, and therefore, there is a lack of 
supporting evidence for placing metamizole in the group of 
drugs recommended for neuropathy therapy. Until now, it 
was suggested that the molecular mechanisms underlying 
the effects of metamizole involve the endogenous opioid [18] 
and endocannabinoid [19] systems, the periaqueductal gray 
matter–rostral ventromedial medulla axis [20], and inhibi-
tion of COX-1/COX-2 [21]. Recently, it has been shown that 
metamizole in the brain reduces microglial activation and, 
thus, has a neuroprotective effect in a model of experimental 
ischemia [22]. Our previous results provide evidence that 
repeated intraperitoneal administration of metamizole for 
7 days diminished neuropathic pain-related symptoms in 
mice after sciatic nerve injury. Moreover, we showed that 
its effect is associated with silencing of spinal macrophage/
microglial activation, consequently reducing the levels of 
pronociceptive cytokines (IL-1beta, XCL1, and CCL2) [23]. 
Further, metamizole exerts very good analgesic effects after 
intraperitoneal administration, and thus, we hypothesized 
that its effectiveness is likely due to changes not only at the 
level of the spinal cord but also in DRG.
Therefore, the goal of our current work was to investigate 
the influence of preemptive and repeated (for 7 days) intra-
peritoneal injection of metamizole on the development of 
tactile and thermal hypersensitivity in rats and its influence 
on cytokine changes at the level of DRG after chronic con-
striction injury (CCI) of the sciatic nerve (Bennett model) 
[24]. The purpose of the research was to demonstrate for the 
first time using RT-qPCR and/or Western blot analysis how 
metamizole administration influences the levels of impor-
tant pronociceptive interleukins (IL-1beta, IL-6, and IL-18) 
and chemokines (CCL1, CCL2, CCL3, CCL4, CCL6, CCL7, 
CCL9, CCL17, and CCL22) in DRG 7 days after CCI.
Materials and methods
Animals and ethical statement
Male Wistar rats (270–300 g) from Charles River Labo-
ratories International, Inc. (Germany) were employed for 
the present study. The rats were housed in cages lined with 
sawdust under a standard 12-/12-h light/dark cycle (lights 
on at 8.00 a.m.) with food and water available ad libitum. 
The animals were allowed to adapt to the environment for 
approximately 5 min prior to behavioral testing. All experi-
ments were conducted according to the guidelines of the 
International Association for the Study of Pain (IASP) [25], 
our previous studies [8–10, 26] and the National Institutes 
of Health (NIH) Guide for the Care and Use of Laboratory 
Animals. The experimental protocol was duly approved by 
the II Local Bioethics Committee branch of the National 
Ethics Committee for Experiments on Animals-based at the 
Maj Institute of Pharmacology, Polish Academy of Sciences 
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(Krakow, Poland), permission numbers 1277/2015 and 
153/2016. Care was taken to minimize animal suffering and 
limit the number of animals used in the experiments (3R 
policy).
Chronic constriction injury of the sciatic nerve
Peripheral neuropathic pain was induced in rats by CCI. In 
brief, CCI was performed under sodium pentobarbital anes-
thesia (60 mg/kg; ip) according to the method described in 
[24] and in our previous publications [8–10, 26]. An incision 
was made below the right hip bone, and subsequently, the 
right sciatic nerve was exposed by separation of the biceps 
femoris and gluteus superficialis. To produce the injury, four 
ligatures were made by loosely tying 4/0 silk thread around 
the sciatic nerve with 1-mm spacing until a brief twitch in 
the respective hind limb was observed. After the nerve liga-
tion, all rats developed long-lasting neuropathic pain.
Drug administration
Metamizole (Met, 500 mg/kg; SANOFI, Germany) was 
dissolved in water for injection and administered intraperi-
toneally (ip) preemptively 16 and 1 h before CCI and then 
twice a day for 7 days. The dose of metamizole was chosen 
based on our previous research [23] and the available lit-
erature [27, 28]. The control group received vehicle (water 
for injection) according to the same schedule. Before drug 
injections, the baseline behaviors of the animals were deter-
mined using von Frey and cold plate tests. No adverse side 
effects of metamizole treatment were observed during the 
experiments.
Behavioral tests
Pain hypersensitivity tests were conducted 60 min after the 
final morning ip injection of metamizole 2 and 7 days after 
CCI, always in the same order: the von Frey test followed 
by the cold plate test.
Tactile sensitivity (von Frey test)
Hypersensitivity to mechanical stimuli was measured in 
naive rats and in the rats subjected to CCI using an auto-
mated von Frey apparatus (Dynamic Plantar Anesthesiome-
ter, cat. no. 37400, Ugo Basile, Italy) as previously described 
[9, 10, 14]. Five minutes before the experiment, the animals 
were placed in transparent plastic cages with wire net floors 
to allow for behavioral accommodation. A series of von Frey 
stimuli up to 26 g were used in our experiments. The mid-
plantar area of the ipsilateral and contralateral hind paws 
was tested, and measurements were recorded automatically 
as described previously [29]. No significant differences in 
contralateral hind paw responses were observed between the 
rats subjected to CCI and the naive rats. Tactile hypersensi-
tivity was assessed 60 min after the final drug administra-
tion. The ipsilateral paw was tested twice at 2-min intervals, 
and the mean value was calculated. No significant differ-
ences in paw reactions were observed between the contralat-
eral hind paws of rats with CCI and naive rats.
Thermal sensitivity (cold plate test)
Hypersensitivity to thermal stimuli was measured using 
a cold plate apparatus (Cold/Hot Plate Analgesia Meter, 
cat. no. 05044/230 VAC, Columbus Instruments, USA) as 
described previously [29]. The temperature of the cold plate 
was kept at 5 °C, and the cut-off latency was set at 30 s. For 
the experiments, the animals were placed on the cold plate, 
and the time to lift the hind paw was recorded.
Gene expression analysis using RT‑qPCR
For quantitative real-time PCR (RT-qPCR) analysis, tissue 
derived from DRG (L4–L6, pooled into one sample) was 
collected from naive rats and CCI rats immediately after 
decapitation on day 7 after repeated metamizole or vehi-
cle treatment. The collected tissue was placed individually 
in tubes containing RNAlater (Qiagen Inc.) and stored at 
− 80 °C until isolation of RNA. Total RNA extraction was 
performed using TRIzol (Invitrogen, Germany) based on 
the protocol described by Chomczynski and Sacchi [30]. 
The RNA quality and concentration were measured with a 
DeNovix DS-11 spectrophotometer (DeNovix Inc., Wilm-
ington, USA). An Omniscript RT Kit (Qiagen Inc., Hilden, 
Germany) was used for reverse transcription, which was 
performed at 37 °C for 60 min using 1 μg of total RNA. 
The reverse transcription reaction mix contained RNAse 
inhibitor (rRNasin, Promega, Mannheim, Germany) and 
oligo (dT16) primer (Qiagen Inc., Hilden, Germany). The 
resulting cDNA was diluted 1:10 with RNase-/DNase-free 
 H2O, and ~ 50 ng of cDNA from each sample was used for 
each RT-qPCR reaction. RT-qPCR was conducted using 
Assay-On-Demand TaqMan probes based on the manu-
facturer’s protocol (Applied Biosystems, Foster City, CA, 
USA) and run in an iCycler device (Bio-Rad, Hercules, 
Warsaw, Poland). The following TaqMan primers and 
probes were used: Rn01527840_m1 (Hprt); Rn00570480_
m1 (C1q); Mm01253033_m1 (GFAP); Rn00580432_m1 
(Il1b); Rn01422083_m1 (Il18); Rn00561420_m1 (Il6); 
Rn01752376_m1 (Ccl1); Rn00580555_m1 (Ccl2); 
Rn01464736_g1 (Ccl3); Rn00671924_m1 (Ccl4); 
Rn01456400_m1 (Ccl6); Rn01467286_m1 (Ccl7); 
Rn01471276_m1 (Ccl9); Rn01536936_g1 (Ccl17); 
Rn01536591_m1 (Ccl22); Rn00592605_m1 (Xcl1). To 
determine the amplification efficiency for each assay 
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(between 1.7 and 2), a standard dilution curve was used. 
The cycle threshold values were calculated automatically 
using CFX Manager v.2.1 software based on the default 
parameters. RNA content was calculated as  2−(threshold cycle). 
The Hprt gene was used as an endogenous control, and its 
expression did not significantly change across the groups 
(data not shown).
Western blot analysis of protein levels
Ipsilateral DRG fragments (L4–L6, pooled into one sample) 
were collected after decapitation, 6 h after the last admin-
istration of metamizole on the 7th day post-CCI. First, the 
tissue lysates were placed in RIPA buffer supplemented with 
a protease inhibitor cocktail and then cleared via centrifuga-
tion (14,000×g for 30 min at 4 °C). All samples (20 μg of 
protein) were heated in loading buffer (4× Laemmli Buffer, 
Bio-Rad, Warsaw, Poland) for 8 min at 98 °C. Next, the 
samples were resolved on 4–15% Criterion™ TGX™ pre-
cast polyacrylamide gels (Bio-Rad, Warsaw, Poland) and 
transferred to Immune-Blot PVDF membranes (Bio-Rad, 
Warsaw, Poland) using a semidry transfer system (30 min, 
25 V). The membranes were blocked with 5% nonfat dry 
milk (Bio-Rad, Warsaw, Poland) in Tris-buffered saline 
with 0.1% Tween 20 (TBST) for 1 h at room temperature, 
washed with TBST, and incubated overnight at 4 °C with 
the following commercially available primary antibodies: 
anti-Iba-1 (1:1000, Proteintech 10904-1-AP), anti-GFAP 
(1:10,000, Novus NB300-141), anti-IL-1beta (1:500, Abcam 
ab9787), anti-IL-18 (1:500, Abcam ab191860), and anti-
IL-6 (1:500, Proteintech 21685-1AP). Then, the membranes 
were incubated with 1:5000 dilutions of horseradish peroxi-
dase-conjugated anti-rabbit secondary antibody for 1 h. The 
solutions from a SignalBoost™ Immunoreaction Enhancer 
Kit (Merck Millipore Darmstadt, Germany) were applied to 
dilute the used antibodies. Afterwards, the membranes were 
washed using TBST. The immune complexes were detected 
using Clarity™ Western ECL Substrate (Bio-Rad, Warsaw, 
Poland) and visualized using a Fujifilm LAS-4000 Fluor-
Imager system. Fujifilm Multi Gauge software was used to 
estimate the density of immunoreactive bands.
Statistical analysis
The behavioral data (Fig.  1) are presented as the 
mean ± SEM. Sample sizes were determined based on our 
previous experiments. The results were evaluated using one-
way ANOVA followed by Bonferroni’s multiple compari-
sons post hoc test of selected pairs. Additionally, the results 
were evaluated using one-way ANOVA with repeated meas-
urements to assess differences in behavioral effects between 
two measured time points and using two-way ANOVA to 
determine the time × drug interaction. The RT-qPCR/
Western blot analysis data (Figs. 2, 3, 4) are presented as 
the fold change relative to the controls (naive rats) ± SEM 
and were calculated for the ipsilateral side of the DRG. Dif-
ferences between the groups were evaluated using one-way 
ANOVA followed by Bonferroni’s multiple comparisons 
post hoc test. All graphs were constructed and statistical 
analyses were performed using Prism software (GraphPad 
Software, Inc., USA). Differences between the group means 
were considered significant when p < 0.05.
Results
The influence of metamizole on pain‑related 
behaviors 2 and 7 days after CCI
The effects of repeated ip administration of metamizole 
(500 mg/kg) were studied in rats after CCI (Fig. 1a, b). Naive 
animals reacted to mechanical stimuli weighing 24.2 ± 0.8 g 
(on the 2nd day) and 25.4 ± 0.3 g (on the 7th day) as meas-
ured by the von Frey test and responded to low temperature 
after 29 ± 0.5 s of exposure (on the 2nd day) and 28.3 ± 0.8 s 
of exposure (on the 7th day) in the cold plate test. Two and 
seven days after CCI, all rats exhibited strong mechani-
cal (12.8 ± 1.7 and 13.2 ± 0.6 g, respectively; Fig. 1a) and 
potent thermal (8.4 ± 0.8 and 11.7 ± 1.1  s, respectively; 
Fig. 1b) hypersensitivity in the paw ipsilateral to the injury. 
Metamizole significantly diminished neuropathic pain symp-
toms on day 2 and even more strongly on day 7 after CCI 
compared with vehicle treatment as measured by the von 
Frey (17 ± 0.9 g vs. 12.8 ± 1.7; F(2,27) = 22.5; p < 0.0001 and 
20.8 ± 0.7 g vs. 13.2 ± 0.6; F(2,46) = 83.7; p < 0.0001, respec-
tively; Fig. 1a) and cold plate (15.3 ± 1.3 s vs. 8.4 ± 0.7; 
F(2,29) = 97.6; p < 0.0001 and 24.6 ± 1.1 s vs. 11.7 ± 1.1; 
F(2,46) = 59.5; p < 0.0001, respectively; Fig. 1b) tests. One-
way ANOVA with repeated measurements revealed that 
there was no significant difference in the level of hypersensi-
tivity between the 2nd and 7th days after CCI in both the von 
Frey (F(1,2) = 3.044, p = 0.2232) and cold plate (F(1,2) = 2.303, 
p = 0.2684) tests. However, importantly, two-way ANOVA 
confirmed a significant interaction between the investigated 
treatment and the investigated time points only in the cold 
plate test (F(2,75) = 8.283, p = 0.0006) and not in the von Frey 
test (F(2,73) = 2.001, p = 0.1426).
The influence of metamizole on the levels of C1q/
IBA1 and GFAP in DRG 7 days after CCI
According to RT-qPCR analysis, the C1q level was upregu-
lated from 1 ± 0.1 to 4.2 ± 0.9 (F(2,19) = 7.635; p = 0.0037) in 
rats subjected to CCI compared with naive rats (Fig. 2a). No 
significant differences in the C1q mRNA level were observed 
between the metamizole- and vehicle-treated rats after CCI 
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(Fig. 2a). The mRNA level of GFAP in DRG was upregu-
lated from 1 ± 0.1 to 1.7 ± 0.1 (F(2,25) = 17.88; p < 0.0001) in 
vehicle-treated rats exposed to CCI to 1.88 ± 0.15 in naive 
rats and remained unchanged after metamizole administra-
tion (Fig. 2b).
Through Western blot analysis, we observed an increase 
in the IBA-1 protein level from 1 ± 0.07 in naive animals to 
1.6 ± 0.1 (F(2,19) = 7.032; p = 0.0052) in vehicle-treated rats 
after CCI (Fig. 2c). Repeated administration of metamizole 
in rats exposed to CCI slightly changed the IBA-1 protein 
level, but we did not observe significant differences between 
the vehicle-treated and metamizole-treated rats after CCI 
(Fig. 2c). The GFAP protein level was significantly higher 
in the vehicle-treated rats exposed to CCI than in the naive 
rats (1.5 ± 0.1 vs. 1 ± 0.1; F(2,20) = 10.99; p = 0.0006). How-
ever, the GFAP protein level was unchanged by metamizole 
treatment (Fig. 2d).
The influence of metamizole on IL‑1beta, IL‑18 
and IL‑6 levels in DRG 7 days after CCI
The mRNA level of IL-1beta was upregulated from 1 ± 0.06 
to 1.7 ± 0.1 in rats subjected to CCI compared with naive 
rats (Fig. 3a). Metamizole significantly decreased the CCI-
induced elevation in IL-1beta level from 1.7 ± 0.1 to 1.2 ± 0.1 
(F(2,25) = 14.97; p < 0.0001). Moreover, we observed sig-
nificant upregulation of the IL-18 level from 1 ± 0.03 to 
1.52 ± 0.09 in rats after CCI compared with naive rats, and 
metamizole effectively diminished the IL-18 level from 
1.5 ± 0.1 to 1.3 ± 0.1 (F(2,23) = 12.57; p = 0.0002) (Fig. 3b). 
Additionally, the IL-6 mRNA level was strongly upregulated 
from 1 ± 0.1 to 74.6 ± 3.7 in rats exposed to CCI compared 
with naive rats (Fig. 3c). The level of IL-6 decreased from 
74.6 ± 3.7 to 61.0 ± 4.7 (F(2,24) = 135.8; p < 0.0001) in rats 
that received repeated metamizole treatment compared with 
vehicle-treated rats subjected to CCI (Fig. 3c).
Western blot analysis showed that the protein level of IL-
1beta in rats after CCI was unchanged compared with that 
in naive rats, and metamizole treatment did not affect the 
IL-1beta protein levels (F(2,18) = 2.015; p = 0.1623) (Fig. 3d). 
However, at the same time point, we observed a significant 
increase in the protein level of IL-18 from 1 ± 0.1 to 1.4 ± 0.1 
(F(2,16) = 4.786; p = 0.0235) in the vehicle-treated rats com-
pared with the naive animals, and metamizole administration 
Fig. 1  The effects of metamizole administration on neuropathic pain 
symptoms in rats after CCI. Metamizole (500 mg/kg, ip) was injected 
16 h and 1 h before CCI and then twice a day for 7 days. Behavioral 
evaluations were performed 1 h after the final morning drug admin-
istration on days 2 and 7 after CCI. The influence of repeated meta-
mizole administration on the development of mechanical (a von Frey 
test) and thermal (b cold plate test) hypersensitivity in rats exposed 
to CCI was evaluated. The data are presented as the mean ± SEM. 
On day 2, n = 10 rats per group were evaluated. On day 7, the num-
bers of rats evaluated per group were as follows: n = 10 in the naive 
group; n = 19–20 in the VEH- and MET-treated groups. Intergroup 
differences were analyzed using one-way ANOVA followed by 
Bonferroni’s multiple comparison test. *p < 0.05, **p < 0.01, and 
***p < 0.001 indicate significant differences compared with the naive 
group; #p < 0.05 and ###p < 0.001 indicate significant differences com-
pared with the vehicle-treated rats after CCI. Additionally, the results 
were evaluated using one-way ANOVA with repeated measurements 
to determine differences in behavioral effects between examined time 
points and using two-way ANOVA to determine the time × drug inter-
action. CCI chronic constriction injury, MET metamizole, VEH vehi-
cle, N naive
▸
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did not significantly change the IL-18 protein level (Fig. 3e). 
Furthermore, we observed an increase in the protein level 
of IL-6 in the vehicle-treated rats exposed to CCI compared 
with the control group from 1 ± 0.2 to 1.4 ± 0.1, and admin-
istration of metamizole significantly diminished the CCI-
induced elevation in the IL-6 protein level from 1.4 ± 0.1 to 
1.03 ± 0.06 (F(2,15) = 6.335; p = 0.0101) (Fig. 3f).
The influence of metamizole on the studied 
chemokine mRNA levels in DRG 7 days after CCI
RT-qPCR analysis of DRG showed a significant increase in 
the level of CCL1 from 1 ± 0.2 to 1.7 ± 0.3 (Fig. 4a), CCL2 
from 1 ± 0.1 to 2.2 ± 0.1 (Fig. 4b), CCL3 from 1 ± 0.05 
to 1.3 ± 0.1 (Fig.  4c), CCL4 from 1 ± 0.04 to 1.3 ± 0.1 
(Fig. 4d), CCL6 from 1 ± 0.1 to 1.5 ± 0.6 (Fig. 4e), CCL7 
from 1 ± 0.03 to 1.4 ± 0.1 (Fig. 4f), CCL9 from 1 ± 0.1 to 
2.2 ± 0.3 (Fig. 4g), CCL17 from 1 ± 0.1 to 1.7 ± 0.7 (Fig. 4h), 
CCL22 from 1 ± 0.1 to 1.9 ± 0.25 (Fig. 4i), and XCL1 from 
1 ± 0.1 to 7.9 ± 0.6 (Fig. 4j) in vehicle-treated rats exposed 
to CCI compared with naive animals.
Compared to vehicle treatment, repeated ip metami-
zole administration significantly attenuated the mRNA 
levels of CCL2 from 2.2 ± 0.1 to 1.8 ± 0.1 (F(2,22) = 51.05; 
p < 0.0001) (Fig. 4b), CCL4 from 1.3 ± 0.1 to 1.05 ± 0.1 
(F (2,21) = 5.709; p  = 0.0105) (Fig.  4d) and CCL7 
from 1.4 ± 0.1 to 1.2 ± 0.1 (F(2,20) = 7.11; p = 0.0047) 
(Fig. 4f) in rats after CCI. Additionally, we observed 
Fig. 2  The effects of meta-
mizole administration on the 
mRNA and protein levels of 
C1q/IBA1 and GFAP in the 
dorsal root ganglia (DRG) of 
rats after CCI. The effects of 
repeated metamizole adminis-
tration (500 mg/kg, ip, 16 and 
1 h before CCI and then twice 
a day for 7 days) on the mRNA 
(upper panel) and protein 
(lower panel) levels of the 
glial markers C1q (a), IBA-1 
(c), and GFAP (b, d) in DRG 
7 days after CCI. The data are 
presented as the mean ± SEM 
of 6–8 samples from each 
group. Intergroup differences 
were analyzed using one-way 
ANOVA with Bonferroni’s mul-
tiple comparison test. *p < 0.05, 
**p < 0.01 and ***p < 0.001 
indicate significant differences 
compared with naive rats. CCI 
chronic constriction injury, 
MET metamizole, VEH vehicle, 
N naive
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that metamizole did not influence the mRNA levels of 
CCL1 (Fig. 4a), CCL6 (Fig. 4e) or CCL9 (Fig. 4g), with 
these levels approaching the levels observed in the naive 
group. In addition, unlike those of the abovementioned 
chemokines, the elevated CCL1, CCL3, CCL6, CCL9, 
CCL17, CCL22, and XCL1 levels induced by CCI were 
not diminished by metamizole treatment (Fig. 4a, c, e, 
g–j, respectively).
Discussion
Our study showed that metamizole administration reduces 
tactile and thermal hypersensitivity in rats after CCI. Our 
animal model mimics the characteristic features of neu-
ropathic pain in humans [24] and has been used in our 
previous experiments [7–11]. Our behavioral results are 
Fig. 3  The effects of metamizole administration on the mRNA and 
protein levels of pronociceptive factors in the dorsal root ganglia 
(DRG) of rats after CCI. The effects of repeated metamizole admin-
istration (500 mg/kg, ip, 16 and 1 h before CCI and then twice a day 
for 7  days) on the mRNA (upper panel) and protein (lower panel) 
levels of the pronociceptive factors IL-1beta (a, d), IL-18 (b, e), and 
IL-6 (c, f) in DRG 7  days after CCI. The data are presented as the 
mean ± SEM of 6–8 samples from each group. Intergroup differences 
were analyzed using one-way ANOVA with Bonferroni’s multiple 
comparison test. *p < 0.05 and ***p < 0.001 indicate differences com-
pared with naive rats. #p < 0.05 and ###p < 0.001 indicate differences 
compared with vehicle-treated rats after CCI. CCI chronic constric-
tion injury, MET metamizole, VEH vehicle, N naive
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in agreement with research by Nassini et al. [31] and Ince 
et al. [28], who found that metamizole not only prevents 
pain induced by scalpel incision in the rat paw but also 
diminishes tactile hypersensitivity in inflammatory (for-
malin, carrageenan) and neuropathic (partial sciatic nerve 
ligation) pain models. Moreover, it has already been shown 
that metamizole reduces hypersensitivity in neuropathy 
induced by diabetes [32] and cancer [33]. Here, for the 
first time, we showed that metamizole influences several 
immunological pronociceptive factors in DRG. To inves-
tigate the molecular background of the observed analgesic 
effects of metamizole, we chose to further study pronoci-
ceptive factors, which undoubtedly play an important role 
in nociception at the DRG level [5, 7–11, 14].
Primary afferent sensory neurons are responsible for 
nociceptive transmission, and their cell bodies are located in 
DRG. Data from previous studies indicate that resident mac-
rophages are normally present in DRG, alongside satellite 
glial cells, and though remote from the lesion site, they react 
to nerve injury by releasing cytokines [34]. In the first week 
after nerve injury, macrophages flow into DRG [34]. Cur-
rently, it is known that in addition to resident and recruited 
immune cells present throughout the neuraxis, cytokines are 
released from neuronal cells [35]. Thus, cytokines compose 
a communication network between immune and neuronal 
cells. Interleukins (IL-1beta, IL-18 and IL-6) are recognized 
as the first pronociceptive cytokines in neuropathy [35] and 
are known to be strongly activated upon neural damage 
in the CNS and PNS [35–39]. In our previous studies, we 
showed that minocycline administered ip has an analgesic 
effect in parallel with diminished immunological factors, 
such as IL-1beta and IL-18 in DRG [40, 41]. Furthermore, 
it is worth noting that Botulinum toxin A, which was found 
to directly affect neuronal transmission, also decreases IL-
1beta and IL-18 levels in DRG [41]. Numerous experimental 
and clinical studies have suggested that cytokines are good 
Fig. 4  The effects of metamizole administration on mRNA levels of 
chemokines in the dorsal root ganglia (DRG) of rats after CCI. The 
effects of repeated metamizole administration (500  mg/kg, ip, 16  h 
and 1 h before CCI and then twice a day for 7 days) on the mRNA 
levels of CCL1 (a), CCL2 (b), CCL3 (c), CCL4 (d), CCL6 (e), CCL7 
(f), CCL9 (g), CCL17 (h), CCL22 (i), and XCL1 (j) in DRG 7 days 
after CCI. The data are presented as the mean ± SEM of 6–8 samples 
from each group. Intergroup differences were analyzed using one-
way ANOVA with Bonferroni’s multiple comparison test. *p < 0.05, 
**p < 0.01 and ***p < 0.001 indicate differences compared with naive 
rats. #p < 0.05 and ##p < 0.01 indicate differences compared with vehi-
cle-treated rats after CCI. CCI chronic constriction injury, MET meta-
mizole, VEH vehicle, N naive
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targets for therapy. ACZ885, a monoclonal antibody that 
neutralizes IL-1beta, is known to reduce rheumatoid arthri-
tis symptoms in mice and humans [42]. Moreover, admin-
istration of anti-IL-1beta antibody [43] and IL-18BP [44] 
reduced neuropathic pain in rodents. There is solid clinical 
evidence supporting IL-6 as a potential therapeutic target 
in pain states [38]. Anti-IL-6 neutralizing antibodies, such 
as tocilizumab, clazakizumab, olokizumab, and sarilumab, 
are already being used in the clinic [45–47]. For example, 
two separate prospective cohort studies have suggested 
some benefit of tocilizumab in patients with low back pain 
[46, 47]. For postoperative pain, it has been demonstrated 
in humans that pretreatment with pentoxifylline can dimin-
ish the opioid requirement in the early postcholecystectomy 
operative period, as well as TNF-α and IL-1beta serum lev-
els [48].
In our previous studies, we demonstrated for the first 
time that repeated administration of metamizole strongly 
suppresses the CCI-induced activation of microglial but not 
astroglial cells [23]. In vitro studies performed in a human 
monocytic cell line showed that metamizole also has an 
inhibitory effect on monocyte activation and can potently 
suppress chemokine production [49]. Here, we observed 
strong activation of monocytes/macrophages and satellite 
cells in DRG 7 days after sciatic nerve injury, which is in 
agreement with our previous findings [40, 41, 44]. How-
ever, metamizole did not significantly suppress the changes 
in these levels. In our previous studies [23], we demonstrated 
that metamizole did not suppress astrocyte activation. Thus, 
we can assume that the mechanism underlying the action 
of metamizole does not involve GFAP-positive cells in the 
nervous system. However, we observed that metamizole 
reduced the CCI-induced elevations in the mRNA levels of 
the pronociceptive IL-1beta, IL-6 and IL-18 cytokines. IL-
1beta is known to be strongly activated at the DRG level 
upon neural damage [50], and intrathecal IL-1beta adminis-
tration induces hypersensitivity in rats [4, 36, 51]. Recently, 
little evidence has been presented concerning the effect of 
metamizole on IL-1beta in neuropathic pain. In 2018, we 
showed [23] that metamizole diminishes the spinal level 
of IL-1beta in a mouse model of neuropathic pain. Simi-
larly, Zhang et al. [22] showed that intracerebroventricular 
injections of metamizole strongly reduce the upregulation 
of IL-1beta in a cerebral ischemia model. IL-18 is another 
cytokine belonging to the IL-1 superfamily and has prono-
ciceptive properties during the development of neuropathic 
pain [44, 52]. It has been shown that IL-18 is upregulated 
in spinal microglia after peripheral nerve injury and that 
an anti-IL-18 antibody attenuates injury-induced mechani-
cal hypersensitivity in rats [39]. In the current study, we 
observed that CCI induces upregulation of IL-18 mRNA and 
protein levels in DRG, which is consistent with other studies 
[40, 44, 53]. Moreover, we provided the first evidence that 
metamizole significantly prevents the CCI-induced upregu-
lation of IL-18 mRNA in DRG and that this upregulation 
may be crucial for the analgesic properties of metamizole. 
It is well known that IL-6 plays a key role in neuropathic 
pain development [4, 54]. Here, we confirmed that the level 
of IL-6 mRNA is strongly enhanced in rat DRG after CCI, 
and similar results have been published previously [40, 50]. 
It was previously reported that administration of IL-6 neu-
tralizing antibodies diminishes pain behavior in neuropathic 
pain models [55]. We demonstrated that metamizole sig-
nificantly reduces the mRNA and protein levels of IL-6 in 
DRG, which might be one of the reasons for its beneficial 
properties.
Chemokines are a family of small chemotactic molecules 
responsible for attracting circulating leukocytes, especially 
granulocytes, lymphocytes, and monocytes, to the site of 
injury. They are produced by immune cells and by neurons, 
microglia and astrocytes [56]. Many chemokines from 
the CC-, CXC- and XC subfamilies are involved in noci-
ceptive transmission [7, 9–11, 56–58]. Previously, it was 
demonstrated that some chemokines are upregulated after 
peripheral nerve injury not only in the spinal cord but also 
in DRG [11]. Moreover, our recent studies have shown that 
the most pronounced upregulation in DRG at 7 days post-
CCI is observed for chemokines in the CC- subfamily [7, 
11]. Thus, CC chemokines seem to be an interesting target 
for pharmacological modulation. Here, we confirmed the 
upregulation of CCL1, CCL2, CCL3, CCL4, CCL6, CCL7, 
CCL9, CCL17, and CCL22 mRNA levels in DRG 7 days 
after peripheral nerve injury in rats.
In 2013, it was reported that CCL1 expression is increased 
in DRG after partial sciatic nerve ligation in mice [59]; this 
finding is in agreement with the results we observed in rats. 
It has also been shown that CCL1 is a crucial factor in the 
pathogenesis of neuropathic pain induced by diabetes [58]. 
Here, we did not observe any changes in the level of CCL1 
after repeated administration of metamizole.
CCL2 is a significant pronociceptive mediator. Recently, 
Piotrowska et al. [9] and Kwiatkowski et al. [8] reported 
that modulation of the CCL2/CCR2 pathway by a CCR2 
antagonist reduced neuropathic pain development in rats. 
Intrathecal administration of CCL2 leads to both thermal 
and mechanical sensitization, whereas injection of anti-
CCL2 neutralizing antibodies suppresses the development 
of hypersensitivity [60, 61]. We have already shown that 
metamizole reduces the spinal level of CCL2 in a mouse 
model of neuropathic pain [23]. Our current results provide 
new evidence that CCL2 is undoubtedly involved at the DRG 
level in the analgesic effects of metamizole in neuropathic 
pain.
The chemokines CCL3, CCL4, and CCL9 are members 
of the macrophage inflammatory protein-1 (MIP-1) fam-
ily. It has been previously shown that CCL3 and CCL4 are 
1319Metamizole relieves pain by influencing cytokine levels in dorsal root ganglia in a rat model…
1 3
produced by activated macrophages and Schwann cells in 
the injured nerve; thus, they have been postulated to be key 
participants in the development of pain at the site of injury 
[62, 63]. Recent data have shown that intrathecal injection 
of CCL3, CCL4, or CCL9 evokes strong pain-like behav-
ior in naive mice [64]. Additionally, direct neutralization of 
CCL3 or CCL9 decreases pain-related behaviors in diabe-
tes- [64] and paclitaxel-induced neuropathy [65]. Further-
more, intrathecal injections of the selective CCR5 antagonist 
maraviroc significantly decreased the levels of CCR5 pro-
nociceptive ligands, including CCL3 and CCL4, and thus 
reduced neuropathic pain symptoms after CCI of the sciatic 
nerve [11]. The findings of our present study show that the 
analgesic effect of metamizole is strongly associated with a 
reduction in CCL4 expression in DRG.
The role of CCL6 in neuropathic pain still needs to be 
clarified. Recently, we observed significant time-dependent 
changes in the CCL6 mRNA level in DRG starting at day 7 
and lasting until day 28 after CCI [53]. In our current study, 
we observed that metamizole diminishes the CCI-induced 
elevation in the CCL6 level. Thus, little is known about the 
role of this chemokine in neuropathy, and further studies 
are needed.
In painful neuropathy, upregulated CCL7 levels have 
also been observed in DRG [11, 66]. Moreover, intrathecal 
administration of CCL7 strongly induces mechanical and 
thermal hypersensitivity in naive mice, and administration 
of neutralizing antibodies attenuates neuropathic pain in 
mice after CCI [67]. The results confirmed that CCL7 is 
strongly involved in the development of hypersensitivity in 
neuropathy. We provide the first evidence that metamizole 
significantly prevents CCI-induced upregulation of CCL7 in 
DRG, which may have an important impact on the analgesic 
properties of metamizole.
Recent studies have demonstrated increased expression 
of CCL17 in patients suffering from diseases that produce 
pain symptoms, such as fibromyalgia [68], autoimmune 
encephalomyelitis, and multiple sclerosis [69]. Moreover, 
Lee et al. [70] showed that CCL17 is important for the devel-
opment of collagenase-induced osteoarthritis and suggested 
that neutralization of CCL17 might bring therapeutic effects 
[70]. Additionally, it was previously shown that CCL22 is 
involved in the pathogenesis of autoimmune encephalomy-
elitis [69]. For the first time, we have shown that CCL17 
and CCL22 mRNA are upregulated in DRG after sciatic 
nerve injury; however, the levels of these mRNAs remained 
unchanged after metamizole administration. Thus, these 
chemokines are likely not involved in the beneficial effects 
of metamizole, and therefore, the involvement of CCL17 and 
CCL22 in neuropathic pain remains unknown.
Interestingly, for the first time, we observed strong 
upregulation of chemokines from the XC subfamily, namely, 
XCL1, at the DRG level. Our previous studies [57] showed 
that spinal XCL1 plays an important role in diabetic neuro-
pathic pain. Moreover, we have previously shown that meta-
mizole diminishes XCL1 expression at the spinal cord level 
in a model of neuropathy [23]; however, our current results 
indicate that this is not a case at the DRG level.
Conclusions
Millions of people worldwide suffer from neuropathic pain 
as a consequence of nervous system dysfunction in the 
course of numerous diseases. Development of effective 
therapeutic strategies requires a better understanding of the 
molecular mechanisms underlying the pathogenesis of neu-
ropathy. This study is an original step toward understanding 
the actions of metamizole in neuropathic pain. Our findings 
in a rat model of neuropathic pain provide evidence that 
metamizole exhibits beneficial analgesic effects by modu-
lating the complex neuro-immunological interactions medi-
ated by interleukins and chemokines at the DRG level. Our 
results show for the first time that pronociceptive factors, 
such as IL-1beta, IL-6, IL-18, CCL2, CCL4, and CCL7, 
play an important role in the analgesic activity of metami-
zole. Additionally, we suggest that the beneficial effects of 
metamizole result from a significant reduction in not only 
the levels of the abovementioned factors but also those of 
other chemokines, which are only slightly decreased after 
treatment. Overall, in our opinion, metamizole should be 
added to the modest arsenal of effective remedies for neu-
ropathic pain.
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